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Abstract
Background: A promoter capable of driving high-level transgene expression in oviduct cells is important for
developing transgenic chickens capable of producing therapeutic proteins, including monoclonal antibodies
(mAbs), in the whites of laid eggs. Ovalbumin promoters can be used as oviduct-specific regulatory sequences in
transgenic chickens, but their promoter activities are not high, according to previous reports.
Results: In this study, while using a previously characterized ovalbumin promoter, we attempted to improve the
expression level of mAbs using a Cre/loxP-mediated conditional excision system. We constructed a therapeutic
mAb expression vector, pBS-DS-hIgG, driven by the CMV and CAG promoters, in which the expression of the heavy
and light chains of humanized immunoglobulin G (hIgG) is preceded by two floxed stuffer reporter genes. In the
presence of Cre, the stuffer genes were precisely excised and hIgG expression was induced in pBS-DS-hIgG-
transfected 293T cells. In chicken oviduct primary culture cells, hIgG was expressed after transfection of pBS-DS-
hIgG together with the ovalbumin promoter-driven Cre expression vector. The expression level of hIgG in these
cells was increased 40-fold over that induced directly by the ovalbumin promoter. On the other hand, hIgG was
not induced by the ovalbumin promoter-driven Cre in chicken embryonic fibroblast cells.
Conclusions: The Cre/loxP-based system could significantly increase ovalbumin promoter-driven production of
proteins of interest, specifically in oviduct cells. This expression system could be useful for producing therapeutic
mAbs at high level using transgenic chickens as bioreactors.
Background
The market for therapeutic monoclonal antibodies
(mAbs) has dramatically expanded over the past decade
because of their high clinical efficacy. In the U.S.,
around 30 mAbs are currently approved for therapeutic
use in cancers, autoimmune disorders, and infectious
diseases, and the number of available mAb products is
predicted to increase [1,2]. Although therapeutic mAbs
have become a major class of drugs, their high produc-
tion cost is a major obstacle. This is mainly due to the
use of cultured mammalian cells in the manufacturing
of mAbs, which requires a complex industrial bioreactor
system. To reduce the cost of mAb production, a more
convenient method to replace mammalian cell culture is
required.
One alternative method involves generating transgenic
farm animals as living bioreactors that produce high-
yield therapeutic mAbs in milk or other secretory fluids,
such as egg whites. The production of recombinant
pharmaceutical proteins has been demonstrated in
transgenic animals including sheep, goats, cattle, rabbits,
and chickens (reviewed in [3,4]). Among these animals,
the use of transgenic chickens as bioreactors is expected
to have several advantages, including a shorter timescale
for setup, ease of scaling up, and small space require-
ments (reviewed in [5,6]). Several groups reported the
production of therapeutic proteins, such as cytokines,
mini-antibodies, and mAbs using transgenic chickens
[7-11]. In these transgenic chickens, ubiquitous promo-
ters were used to express the transgenic products; thus,
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not demonstrated.
Compared to tissue-restricted expression, ubiquitous
expression of therapeutic mAbs in transgenic chickens
will increase the heterogeneity of oligosaccharide struc-
ture of mAbs due to the glycosylation in various type of
cells [11,12]. In addition, depending on the antigen
recognition, whole-body expression of foreign mAb
could be the risk of negatively affecting the development
and health of the transgenic chickens. Therefore, ovi-
duct-specific mAb expression is desirable to synthesize
mAbs as a component of egg whites. Using chicken
ovalbumin promoters, two groups demonstrated ovi-
duct-specific expression of therapeutic proteins in trans-
genic chickens and secretion of these proteins into the
egg whites [12,13] However, expression levels of exogen-
o u sp r o t e i n si nt h ee g gw h i t e sd r i v e nb yo v a l b u m i n
promoters were not high (<0.5 mg/ml, egg whites) com-
pared to their expression in the mammalian cell culture
bioreactor (1-13 mg/ml, culture media) [13,14]. Thus, a
highly efficient oviduct promoter is demanded but such
a promoter has not been developed [5].
In an attempt to increase the expression level of thera-
peutic mAbs in chicken oviduct cells, we developed a
Cre-loxP-regulated exogenous immunoglobulin G (IgG)
expression vector. The vector consists of two tandem
expression units, each containing a strong promoter, a
fluorescent gene flanked by loxPo rm u t a n tloxPa sa
stuffer fragment, and the gene for the heavy chain or
light chain of humanized IgG (hIgG) encoding the
human therapeutic mAb, trastuzumab. Trastuzumab
recognizes human epidermal growth facter receptor 2
(HER2), and is clinically used to treat breast cancer.
Cre-dependent hIgG induction was observed in mam-
malian cultured cells as well as laying hen-derived ovi-
duct primary cultured cells following vector transfection.
We quantified the expression level of hIgG and observed
the 40-fold enhancement of hIgG expression compared
to that induced by the ovalbumin promoter as a result
of Cre-dependent transcriptional activation.
Results and Discussion
To enhance the activity of the ovalbumin promoter and
induce efficient production of hIgG in chicken oviduct
cells, we utilized a Cre-loxP-based conditional gene
induction system. The induction system consists of two
vectors: pBS-DS-hIgG, an IgG expression vector with
two stuffer sequences flanked by loxP and modified loxP
(loxP511) sites, and pBS-Ova2.8-Cre, a Cre recombinase
expression vector driven by an oviduct-specific ovalbu-
min promoter contained in a 2.8-kb fragment at the 5’
end of the coding sequence of the chicken ovalbumin
gene (Ova2.8) (Figure. 1A and 1C). In the absence of
Cre recombinase, pBS-DS-hIgG expresses mCherry and
EGFP encoded in the stuffer genes, while in the pre-
sence of Cre recombinase, the two stuffer DNAs are
excised and hIgG light and heavy chain expression
commences simultaneously (Figure 1B). Therefore, co-
introduction of pBS-Ova2.8-Cre with pBS-DS-hIgG
results in oviduct cell-specific Cre-mediated recombina-
tion and expression of hIgG driven by two strong promo-
ters, CAG and CMV. In addition to these two vectors, we
constructed an ovalbumin promoter-driven hIgG expres-
sion vector as a control. This vector consists of two tan-
dem Ova2.8 sequences linked with the light and heavy
chains of hIgG (pBS-Ova2.8-hIgG; Figure. 1D).
Prior to evaluating the vectors in oviduct cells, we
analyzed whether pBS-DS-hIgG functioned as expected
in cultured mammalian cells. To examine whether both
CAG and CMV promoters of pBS-DS-hIgG were active
in the same cells, we transfected pBS-DS-hIgG into
293T cells. As shown in Figure. 2A (second row), EGFP
(green) and mCherry (red) signals were observed in the
transfected cells. Because the signals of EGFP and
mCherry were mostly overlapping, both CAG and CMV
promoters functioned simultaneously in the transfected
cells. Next, we tested whether the two stuffer DNAs in
the pBS-DS-hIgG vector could be excised by Cre recom-
binase. A CMV-driven Cre expression vector (pCMV-
Cre) was constructed and co-transfected with the
pBS-DS-hIgG vector into 293T cells. Following Cre
expression, both EGFP and mCherry fluorescence disap-
peared in a Cre dose-dependent manner (Figure 2, third
and bottom rows). These results suggest that Cre
recombinase excised the two floxed stuffer DNAs in the
pBS-DS-hIgG vector. Consistent with this idea, hIgG
expression was induced by Cre recombinase. 293T cells
were transfected with pBS-DS-hIgG alone or in combi-
nation with pCMV-Cre, and production of hIgG in the
culture media was assessed by immunoblotting. As
shown in Figure 2B, hIgG expression was observed
when pBS-DS-hIgG was transfected with pCMV-Cre,
but not pBS-DS-hIgG alone. In the non-reduced condi-
tion, anti-human IgG (Fc) antibody recognized a single
band with the same mobility as the recombinant control
hIgG protein, trastuzumab (whole antibody). Further-
more, under the reduced condition, anti-human IgG
(H+L) antibody detected the heavy and light chains of
hIgG in the media of pBS-DS-hIgG and pCMV-Cre co-
transfected cells with the same sizes of heavy and light
chains of trastuzumab (Figure 2C). These results indi-
cate that Cre-mediated recombination of the pBS-DS-
hIgG vector caused the excision of floxed stuffer
sequences and the expression of the hIgG complex as a
whole antibody similar to trastuzumab for clinical use.
N e x t ,w ee x a m i n e dC r e - m e d i a t e dh I g Gi n d u c t i o nb y
p B S - D S - h I g Gt r a n s f e c t i o ni nc h i c k e no v i d u c tc e l l s .W e
isolated cells from the oviducts of laying hens and
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secreted ovalbumin in culture media (Figure 3A), sug-
gesting that ovalbumin expression was activated in the
cells. To evaluate the production of hIgG in oviduct
cells, the genes were transfected into primary cultured
oviduct cells. After two days of culture, secreted hIgG
in cell media was analyzed by immunoblotting. As
s h o w ni nF i g u r e3 B ,c o - t r a n s f e c t i o no fp B S - D S - h I g G
and pCMV-Cre into primary cultured oviduct cells
r e s u l t si na b u n d a n tp r o d u c t i o no fh I g Gi nt h ec u l t u r e
supernatant. hIgG was not detected when pBS-DS-
hIgG was transfected alone, but it was clearly observed
when pBS-DS-hIgG was co-transfected with pBS-
Ova2.8-Cre. Interestingly, obvious hIgG expression was
hardly detected in the culture media of oviduct cells
transfected with pBS-Ova2.8-hIgG alone. These results
indicate that hIgG expression driven by the ovalbumin
promoter was enhanced by Cre-loxP-based conditional
gene induction system in oviduct cells. Consistent with
this idea, enhancement of the ovalbumin promoter was
not observed in non-oviduct cells. As shown in Figure
3C, hIgG expression was not observed when pBS-
DS-hIgG was co-transfected with pBS-Ova2.8-Cre in
chicken embryonic fibroblast cells. Taken together,
these results suggest that following co-transfection of
pBS-DS-hIgG with pBS-Ova2.8-Cre in oviduct primary
cultured cells, specific expression of Cre driven by the
Ova2.8 promoter excises the stuffer genes in pBS-
DS-hIgG and induces strong expression of hIgG in
oviduct cells.
The concentration of hIgG in the cell media was ana-
lyzed using ELISA (Figure 3D). Consistent with the
immunoblotting results, hIgG was more abundant in the
culture media of oviduct cells co-transfected with pBS-
DS-hIgG and pBS-Ova2.8-Cre (20 ng/ml) than in cells
transfected with pBS-Ova2.8-hIgG alone (0.5 ng/ml).
Thus, in chicken oviduct cells, pBS-DS-hIgG and pBS-
Ova2.8-Cre co-transfection induces a 40-fold greater
expression of hIgG than direct induction of hIgG by the
ovalbumin regulatory sequence Ova2.8.
In a previous report, Ova2.8 was shown to be the reg-
ulatory sequence required for chicken oviduct-restricted
expression in vivo [13]. Transgenic hens carrying
Ova2.8-driven transgenes specifically express the trans-
genic products in oviduct cells, and the products are
secreted into the egg white (>1.5 mg/egg). However,
Figure 1 Schematic representation of the vectors and Cre-mediated recombination. (A) Structure of pBS-DS-hIgG. Before recombination,
neither hIgG light chain nor heavy chain was expressed in the transfected cells because of the insertion of two floxed stuffer sequences located
at the 5’ end of the hIgG genes. (B) Structure of pBS-DS-hIgG after the deletion of two stuffer sequences (ΔDS-hIgG). Following Cre-mediated
recombination of pBS-DS-hIgG, loxP- and loxP511-flanked stuffer DNA sequences are removed, and then hIgG light and heavy chain expression is
driven by the CAG and CMV promoters, respectively. (C) Structure of pBS-Ova2.8-Cre. The vector consists of a 2.8-kb fragment at the 5’ end of
the ATG codon of chicken ovalbumin (Ova2.8), an oviduct-specific regulatory sequence, and the Cre recombinase gene. (D) Structure of the
chicken oviduct-specific hIgG expression vector pBS-Ova2.8-hIgG. In pBS-Ova2.8-hIgG, expression of the hIgG light and heavy chains is
individually promoted by the ovalbumin promoter Ova2.8.
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required for the commercial use of transgenic chickens
as bioreactors to synthesize therapeutic mAbs. In this
study, we succeeded in enhancing hIgG expression
regulated by Ova2.8 in chicken oviduct cells. Although
it is not clear whether the Cre/loxP-based gene induc-
tion system will induce a 40-fold increase in exogenous
gene expression upon its introduction into transgenic
chickens, it is expected that strong promoters will
induce higer hIgG expression in an oviduct-specific
manner.
The size of the transgene unit in pBS-DS-hIgG is over
11 kb. This is larger than the size limitation of the
inserted DNA into viral vectors which used to produce
transgenic chickens, such as avian leukosis virus vector
(size limit 4-5 kb), murine stem cell virus vector
(3-4 kb), and lentiviral vector (≈10 kb). Recently,
through the use of chicken embryonic stem cells and
chicken primordial germ cells, nonviral chicken trans-
genesis has been developed [12,15,16]. With these new
tools, transgenic chickens that carry pBS-DS-hIgG and
pBS-Ova2.8-Cre could be established. The creation of
transgenic hens carrying these transgenes will demon-
strate whether the strategy we have developed can pro-
duce living bioreactors that generate therapeutic mAbs
at high levels in egg whites.
Conclusions
It is essential to develop gene expression system that
allows high level expression of quality proteins both in
Figure 2 Cre-mediated hIgG expression in 293T cells. (A) Cre-mediated reduction of the stuffer gene products in 293T cells. 293T cells were
transfected with the control vector (pBS, top row), pBS-DS-hIgG (second row), or co-transfected with pBS-DS-hIgG and a low or high dose of
the Cre expression vector (pCMV-Cre, third and bottom rows). Forty-eight hours after transfection, cells were visualized under a fluorescent
microscope. Simultaneous expression of EGFP (green) and mCherry (red) was induced from two stuffer genes when cells were transfected only
with pBS-DS-hIgG (second row). The expression of EGFP and mCherry were dramatically reduced by Cre expression in 293T cells (third row). The
reduction of the stuffer gene expression was Cre-dose dependent (third and bottom rows). (B, C) Cre-dependent hIgG induction in 293T cells.
pBS-DS-hIgG was transfected into 293T cells with or without pCMV-Cre. Forty-eight hours after transfection, cell culture supernatants were
collected and analyzed by anti-human IgG Fc immunoblotting in the non-reduced condition (B) or by anti-human IgG (H+L) immunoblotting in
the reduced condition (C). Expression of hIgG was observed when pBS-DS-hIgG was co-transfected with the Cre expression vector (lane 3, A and
C) but not when the IgG expression vector was transfected alone (lane 2, B and C). In the non-reduced condition, hIgG is detectable as a single
band of approximately 150 kDa, and in the reduced condition, two bands of approximately 50 and 25 kDa are detected. Trastuzumab was used
as a recombinant hIgG control (lane 4, B and C).
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method is to use chickens as bioreactors where produc-
tion of proteins of interest is tightly controlled in tissue
specific manner to allow accumulation of the gene pro-
duct only in egg whites. We describe a new method to
produce therapeutic mAbs in chicken oviduct cells. This
method is based on Cre/loxP-mediated conditional exci-
sion system, regulated by oviduct specific ovalbumin
promoter. In oviduct primary cultured cells, we achieved
a 40-fold increase in therapeutic mAb production with
this method compared to the mAb induction directly by
the ovalbumin promoter. High level Oviduct-specific
expression of proteins is required to produce therapeutic
mAbs in the egg white. Therefore, this method offers a
novel strategy practically useful for producing therapeu-
tic proteins in transgenic chickens.
Methods
Transgene construction
T h e2 . 8 - k bf r a g m e n ta tt h e5 ’ end of the coding
sequence of the chicken ovalbumin gene (Ova2.8) was
amplified from chicken genomic DNA by PCR and
modified to create a new Kozak consensus sequence,
essentially as described in a previous report (Table 1)
[13]. The insulator element from the chicken b-globin
locus was isolated by PCR and two copies of the PCR
product were ligated in the same orientation, resulting
in a tandem duplication of the insulator (2xHS4) [16].
Figure 3 Cre-mediated hIgG expression in chicken oviduct primary cultured cells. (A) Expression of ovalbumin protein in oviduct primary
cultured cells. Cell culture supernatants were collected 2 days after culture (culture sup.) or at the beginning of cell culture (control sup.) and
analyzed by anti-ovalbumin immunoblotting. (B) Expression of hIgG in oviduct primary cultured cells. Cells were isolated from laying hen
oviducts as described in Materials and methods. Oviduct primary cultured cells were singly or doubly transfected with the expression vectors, as
shown in the panel. The cell culture supernatants were collected and analyzed by anti-human IgG Fc immunoblotting in the non-reduced
condition. Obvious expression of hIgG was observed when pBS-DS-hIgG was co-transfected with pBS-Ova2.8-Cre or pCMV-Cre. (C) Expression of
hIgG in chicken embryonic fibroblast cells. Fibroblast cells from 9-10 day chicken embryos were transfected with the expression vectors, as
shown in the panel. hIgG expression was analyzed as described above. Expression of hIgG was observed when pBS-DS-hIgG was co-transfected
with pCMV-Cre but not with pBS-Ova2.8-Cre (D) The induction levels of hIgG were examined by ELISA for human IgG. hIgG is abundant in the
media of pBS-DS-hIgG and pBS-Ova2.8-Cre co-transfected oviduct primary culture cells (20 ng/ml) compared to levels in pBS-Ova2.8-hIgG-
transfected cells (0.5 ng/ml). Essentially identical results were obtained in three independent experiments.
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light chain (GI:28948772 1-236aa) and heavy chain
(GI:28948773 1-105aa) were synthesized and ligated to
constant regions of the hIgG light chain (GI:2765423)
and heavy chain (GI:2765421), respectively.
pBS-DS-hIgG consists of 2xHS4, the CAG promoter
of pCAGGS [17], the synthesized loxPs e q u e n c e ,t h e
synthesized prokaryotic promoter em7 sequence, the
neomycin resistance gene PCR amplified from pEGFP-
N1 (Clontech, Mountain View, CA), an IRES sequence
followed by the EGFP gene and SV40 polyA of pIRES2-
EGFP (Clontech), a second loxP sequence, a hIgG light
chain, the bovine growth hormone (BGH) polyA PCR
fragment amplified from pcDNA3 (Invitrogen, Carlsbad,
CA), a second 2xHS4, the CMV promoter of pEGFP-
N1, the synthesized loxP511 sequence, the mCherry
gene (Clontech), a rabbit b-globin (RGB) polyA PCR
fragment amplified from pCAGGS, a second loxP511
sequence, a hIgG heavy chain, a herpes simplex virus
thymidine kinase (HSVTK) polyA sequence amplified
from pEGFP-N1, and a third 2xHS4, in this specific
order. Each primer sequence for PCR amplification and
DNA synthesis is indicated in Table 1. pBS-Ova2.8-Cre
consists of 2xHS4, Ova2.8, Cre gene, BGH polyA, a sec-
ond 2xHS4, the SV40 promoter PCR amplified from
pEGFP-N1, the hygromycin resistance gene, HSVTK
polyA, and a third 2xHS4, in this specific order
(Table 1). pBS-Ova2.8-hIgG consists of 2xHS4, Ova2.8,
a hIgG light chain, BGH polyA, another 2xHS4, a sec-
ond Ova2.8, a hIgG heavy chain, HSVTK polyA, and a
third 2xHS4, in this specific order. pCMV-Cre was con-
structed by ligating the Cre gene into the EcoRI site of
pcDNA3 (Invitrogen).
Cell culture and transfection
293T cells were maintained continuously in DMEM (Invi-
trogen) supplemented with 10% (v/v) fetal calf serum
(FCS). For transfection analysis, cells were plated onto 6-
well plates at 3 × 105 cells/well, and 1.5 μg of plasmid was
transfected using the FuGene 6 (Roch Diagnostics GmbH,
Mannheim, Germany ) transfection reagent according to
the manufacturer’s protocols. Oviduct cells were disso-
ciated from 18-24-month-old laying hens, as described
previously [18,19]. The cells were suspended in DMEM
with 10% FCS containing 1 × 10-7 M 17b-estradiol (Naca-
lai, Tokyo, Japan), 1 × 10-6 M corticosterone (Wako,
Osaka, Japan), and 50 ng/ml insulin (Nacalai) and plated
onto gelatin-coated 12-well plates. After 24-48 h of cul-
ture, cells were grown to 50% confluence and utilized for
transfection studies. Before transfection, culture media
was replaced with Opti-MEM containing 17b-estradiol,
corticosterone, and insulin in the same concentrations as
described above. Plasmids were transfected into oviduct
primary cultured cells using FuGene6 with 0.5 μg of DNA
for 48 h. The total amount of DNA was kept constant
with that of the empty vector.
Table 1 Sequences for PCR primers and synthetic oligo DNAs
Sequences for PCR primers
Ova2.8F 5’-AAGGTACCTTAAGTCCTCAGACTTGGC-3’
Ova2.8R 5’-GCCCCGGGTGAACTCTGAGTTGTCTAG-3’
HS4F 5’-AGGATCCGAAGCAGGCTTTCCTGGAAGG-3’
HS4R 5’-AAGATCTTCAGCCTAAAGCTTTTTCCCCGT-3’
NeoRF 5’-CCGGATCCGATCAAGAGACAGGA-3’
NeoRR 5’-CCAGATCTCAGAAGAACTCGTC-3’
BGHpAF 5’-AGGCCTCGCTGATCAGCCTCG-3’
BGHpAR 5’-AGGTACCGGCCATTACGGCCTGCTATTGTCTTCCCAAT-3’
RGBpAF 5’-CCTCTAGAATTCACTCCTCAGGTGC-3’
RGBpAR 5’-TTGCGGCCGCGGATCCAGGTCGAGGGATCTTCAT-3’
HSVTKpAF 5’-GAATTCTGGGGTTCGAAATGAC-3’
HSVTKpAR 5’-GGATCCTAACCTGAGGCTATGGCA-3’
SV40pF 5’-GATATCTTCAAATATGTATCCGCTCA-3’
SV40pR 5’-GGATCCTCCAAAAAAGCCTCCTCA-3’
Cre-F 5’-GGGTTAACACAACCATGTCCAATTTACTG
Cre-R 5’-TCGGTACCTAATCGCCATCTTC-3’
Sequences for synthetic oligo DNAs
loxP 5’-ATAACTTCGTATAGCATACATTATACGAAGTTAT-3’
loxP511 5’-ATAACTTCGTATAGTATACATTATACGAAGTTAT-3’
Em7 5’-GTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAGGTGAGGAACTAAACC-3’
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Cell culture supernatants and recombinant hIgG protein
(Trastuzumab, Roche) was eluted with non-reducing or
reducing Laemmli sample buffer, separated by SDS-
PAGE, and transferred to polyvinylidene difluoride
membrane filters (Immobilon, Millipore, Bedford, MA).
The membranes were immunoblotted with anti-human
IgG Fc antibody (I-124, Leinco Technologies, St. Louis,
MO) and horseradish peroxidase (HRP)-conjugated anti-
human IgG (H+L) antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA) for the non-reduced and
reduced conditions, respectively. Bound anti-human IgG
Fc antibody was visualized with anti-mouse HRP-conju-
gated antibody using a chemiluminescence reagent
(ImmunoStar, WAKO). Bound anti-human IgG (H+L)
antibody was directly visualized by the chemilumines-
cence reagent. To detect ovalbumin expression, anti-
ovalbumin antibody (Millipore) was utilized for immu-
noblotting experiments.
ELISA
The concentration of human IgG in culture media was
measured by a sandwich ELISA with trastuzumab as the
standard. Ninety-six-well plates (Nunc Maxisorb,
Thermo Fisher Scientific, Rochester, NY) were coated
with 100 μlo f1 0μg/ml anti-human IgG (I-124) per
well overnight at 4°C. Plates were washed twice with
200 μl of Tris-buffered saline (TBS)/0.05% Tween 20
and blocked with 4 × Block Ace (DS Pharma Biomedi-
cal, Osaka, Japan) for 1 h at room temperature. After
three washes, 100 μl of culture media and trastuzumab
standards with 0.02 × Block Ace were added and incu-
bated for 2 h at room temperature. The plates were
washed three times and then incubated with 100 μlo f
100 ng/ml HRP-conjugated anti-human IgG for 1 h.
After three washes, plates were incubated with 100 μl
per well of 3,3’,5,5’-tetramethylbenzidine solution (TMB
One Solution, Promega, Madison, Wisconsin) for 10
min. The reactions were stopped with the addition of
100 μl of 1 M HCl. The optical density of the samples
was measured at 450 nm using a microplate reader
(Molecular Devices, Sunnyvale, CA)
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